Clonidine topical gel - BioDelivery Sciences International

Drug Profile

Clonidine topical gel - BioDelivery Sciences International

Alternative Names: ARC-4558

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arcion Therapeutics
  • Developer BioDelivery Sciences International
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 01 Feb 2017 BioDelivery Sciences returns back worldwide licensing rights for clonidine topical gel to Arcion Therapeutics
  • 13 Dec 2016 Discontinued - Phase-III for Diabetic neuropathies in USA due to lack of efficacy (Topical)
  • 01 Nov 2016 BioDelivery Sciences completes a phase IIb trial for Diabetic neuropathy in USA (NCT02643251)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top